Bispecific antibodies and uses thereof
AssigneeAb Studio Inc.
InventorsYue Liu, Wenyan Cai, Jiadong Shi
Life of this patent
Estimating the term…
Abstract
This disclosure relates to bispecific antibodies or antigen-binding fragments thereof, wherein the bispecific antibodies or antigen-binding fragments thereof specifically bind to two different antigens with different binding affinities.
Claims35
A bispecific antibody or antigen-binding fragment thereof comprising
- a first heavy chain variable region,
- a second heavy chain variable region,
- a first light chain variable region, and
- a second light chain variable region,
- wherein the first heavy chain variable region and the first light chain variable region associate with each other, forming a first antigen binding region that specifically binds to a first antigen, and
- the second heavy chain variable region and the second light chain variable region associate with each other, forming a second antigen binding region that specifically binds to a second antigen, wherein the binding affinity of the first antigen binding region when it binds to the first antigen is at least 10 times greater than the binding affinity of the second antigen binding region when it binds to the second antigen, wherein the first light chain variable region and the second light chain variable region are identical.
-12. (canceled)
(canceled)
(canceled)
-31. (canceled)
An antibody or antigen-binding fragment thereof that binds to CD3 comprising:
- a heavy chain variable region (VH) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR1 amino acid sequence, the VH CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR2 amino acid sequence, and the VH CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VH CDR3 amino acid sequence;
- and
- a light chain variable region (VL) comprising CDRs 1, 2, and 3, wherein the VL CDR1 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR1 amino acid sequence, the VL CDR2 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR2 amino acid sequence, and the VL CDR3 region comprises an amino acid sequence that is at least 80% identical to a selected VL CDR3 amino acid sequence,
- wherein the selected VH CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 22-24, respectively, and the selected VL CDRs 1, 2, 3 amino acid sequences are set forth in SEQ ID NOs:
- 28-30, respectively.
(canceled)
-45. (canceled)
A nucleic acid encoding the bispecific antibody or antigen-binding fragment thereof of claim 52.
(canceled)
-50. (canceled)
The bispecific antibody or antigen-binding fragment thereof of claim 70, wherein
- the first heavy chain variable region (VH1) comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
- 1;
- the second heavy chain variable region (VH2) comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
- 2;
- the first light chain variable region (VL1) comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
- 3;
- and
- the second light chain variable region (VL2) comprises an amino acid sequence that is at least 90% identical to SEQ ID NO:
- 3.
-59. (canceled)
(canceled)
(canceled)
-69. (canceled)
A bispecific antibody or antigen-binding fragment thereof that binds to CD20 and CD3 comprising
- a first polypeptide comprising a first heavy chain variable region (VH1) comprising complementarity determining regions (CDRs) 1, 2, and 3, wherein the VH1 CDR1 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 16, the VH1 CDR2 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 17, and the VH1 CDR3 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 18;
- a second polypeptide comprising a second heavy chain variable region (VH2) comprising CDRs 1, 2, and 3, wherein the VH2 CDR1 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 22, the VH2 CDR2 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 23, and the VH2 CDR3 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:24;
- a third polypeptide comprising a first light chain variable region (VL1) comprising CDRs 1, 2, and 3, wherein the VL1 CDR1 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 28, the VL1 CDR2 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 29, and the VL1 CDR3 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 30;
- and
- a fourth polypeptide comprising a second light chain variable region (VL2) comprising CDRs 1, 2, and 3, wherein the VL2 CDR1 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 28, the VL2 CDR2 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 29, and the VL2 CDR3 region comprises an amino acid sequence that is at least 80% identical to SEQ ID NO:
- 30.
A nucleic acid encoding an immunoglobulin heavy chain or a fragment thereof comprising a heavy chain variable region (VH), wherein the VH comprises a sequence that is at least 97% identical to SEQ ID NO:
- 2, and wherein the VH, when paired with a light chain variable region (VL), binds to CD3.
Dependencies are inferred from the claim text.